ConductScience.org, home

Paper41005705

Efficacy, Safety, and Quality-of-Life Outcomes of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.

Khan AA and 9 others. J Allergy Clin Immunol Pract, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Efficacy, Safety, and Quality-of-Life Outcomes of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis. Papers, record 41005705. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41005705

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Efficacy, Safety, and Quality-of-Life Outcomes of Remibrutinib in Chronic Spontaneous Urticaria: A Systematic Review and Meta-Analysis.
PubMed
Journal
J Allergy Clin Immunol Pract
PubMed
Year
2025
PubMed
Publication types
Journal Article, Systematic Review, Meta-Analysis
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2025-12-29
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Khan AAAhmed Ali
2Riaz AAAbdul Ahad
3Naseer FFaisal
4Fatima NNoor
5Abrar ZZuhair
6Malik LLinta
7Khan JJumana
8Aslam RRaza
9Rab AAAhmed Abdul
10Khan AAllahdad

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Chronic UrticariaMajor topic
PyrimidinesMajor topic
Protein Kinase InhibitorsMajor topic
Humans
Quality of Life
Treatment Outcome
Randomized Controlled Trials as Topic

Source PubMed

Download CSV of topics

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42979487Key Players and Pathways of Mast Cell Activation in Urticaria.J Inflamm Res2026https://conductscience.org/library/papers/42979487PubMed
42836496Remibrutinib as a Therapeutic Option for Solar Urticaria.Photodermatol Photoimmunol Photomed2026https://conductscience.org/library/papers/42836496PubMed
42797344Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.Pharmaceutics2026https://conductscience.org/library/papers/42797344PubMed
42776801Targeted Therapy for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Critical Narrative Review and an Evidence-Graded Approach to Agent Selection.Antibodies (Basel)2026https://conductscience.org/library/papers/42776801PubMed
42645084Emerging and Newly Approved Therapies for Antihistamine-Refractory Chronic Spontaneous Urticaria: A Narrative Review.Diseases2026https://conductscience.org/library/papers/42645084PubMed
42345003Treatment Approaches for Omalizumab-Refractory Chronic Spontaneous Urticaria.J Inflamm Res2026https://conductscience.org/library/papers/42345003PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BTK695PubTator's text mininghttps://conductscience.org/library/genes/695NCBI Gene
IGHE3497PubTator's text mininghttps://conductscience.org/library/genes/3497NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41005705

GET https://conductscience.org/api/papers/v1/41005705/authors